الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 91 |  |  |
| | | from | 91 | | |
Abstract
Bronchogenic carcinoma is the major cause of cancer death around the world, with 1.2 million global deaths per year. Regarding mortality and incidence, lung cancer has been the most common cancer around the world since 1985, both in terms of incidence and. Non–small cell lung cancer (NSCLC) constitutes 85% of lung cancer and it is mainly due to active and passive smoking.
Locally advanced un-resectable NSCLC have for a many years been treated with radiotherapy alone . The use of induction chemotherapy before radiation had been evaluated in many randomized studies and an improvement in overall survival was demonstrated. Recent trials have shown that concurrent chemo-radiotherapy offers a significant survival advantage compared to radiotherapy alone. Based on these data concurrent chemoradiotherapy become the standard of care for patient with good performance status.
Because both induction and concomitant chemo-radiotherapy are better than radiotherapy alone, we assumed that combining induction chemotherapy approach and concomitant chemoradiotherapy approach could result in a extra improvement in treatment results over concomitant chemoradiotherapy alone, This combined modality gives us systemic disease control by the induction chemotherapy and higher locoregional control by concomitant chemoradiation.
The objective of this study is to compare induction chemotherapy before concomitant radio- chemotherapy in locally advanced NSCLC with concomitant chemoradiotherapy alone.